Tags

Type your tag names separated by a space and hit enter

A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma.
Am J Ophthalmol 2003; 135(1):55-63AJ

Abstract

PURPOSE

To compare the intraocular pressure (IOP)-lowering efficacy and safety of topical bimatoprost 0.03% with latanoprost 0.005%.

DESIGN

Multicenter, randomized, investigator-masked clinical trial.

METHODS

After washout of glaucoma medications, ocular hypertension or glaucoma patients were randomly assigned to once-daily bimatoprost 0.03% (n = 133) or latanoprost 0.005% (n = 136) for 6 months. The primary outcome measure was mean change from baseline IOP (8 AM, 12 PM, 4 PM). Secondary measures included mean IOP, ophthalmologic examination, adverse events, and the percentage of patients reaching specific target IOPs.

RESULTS

Mean change from baseline IOP was significantly greater for bimatoprost patients than for latanoprost patients at all measurements on each study visit; 1.5 mm Hg greater at 8 AM (P <.001), 2.2 mm Hg greater at 12 PM (P <.001), and 1.2 mm Hg greater at 4 PM (P =.004) at month 6. At the end of the study, the percentage of patients achieving a > or = 20% IOP decrease was 69% to 82% with bimatoprost and 50% to 62% with latanoprost (P < or = .003). In addition, the distribution of patients achieving target pressures in each range (< or = 13 to < or = 15 mm Hg, >15 to < or = 18 mm Hg, and > 18 mm Hg) showed that bimatoprost produced lower target pressures compared with latanoprost at all times measured (P < or = .026). Few patients were discontinued for adverse events (6 on bimatoprost; 5 on latanoprost). On ophthalmologic examination, conjunctival hyperemia (P <.001) and eyelash growth (P =.064) were more common in bimatoprost patients.

CONCLUSIONS

Bimatoprost is more effective than latanoprost in lowering IOP. Both drugs were well tolerated, with few discontinuations for adverse events.

Authors+Show Affiliations

University of Arizona, Tucson, Arizona, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12504698

Citation

Noecker, Robert S., et al. "A Six-month Randomized Clinical Trial Comparing the Intraocular Pressure-lowering Efficacy of Bimatoprost and Latanoprost in Patients With Ocular Hypertension or Glaucoma." American Journal of Ophthalmology, vol. 135, no. 1, 2003, pp. 55-63.
Noecker RS, Dirks MS, Choplin NT, et al. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003;135(1):55-63.
Noecker, R. S., Dirks, M. S., Choplin, N. T., Bernstein, P., Batoosingh, A. L., & Whitcup, S. M. (2003). A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. American Journal of Ophthalmology, 135(1), pp. 55-63.
Noecker RS, et al. A Six-month Randomized Clinical Trial Comparing the Intraocular Pressure-lowering Efficacy of Bimatoprost and Latanoprost in Patients With Ocular Hypertension or Glaucoma. Am J Ophthalmol. 2003;135(1):55-63. PubMed PMID: 12504698.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. AU - Noecker,Robert S, AU - Dirks,Monte S, AU - Choplin,Neil T, AU - Bernstein,Paula, AU - Batoosingh,Amy L, AU - Whitcup,Scott M, AU - ,, PY - 2002/12/31/pubmed PY - 2003/1/28/medline PY - 2002/12/31/entrez SP - 55 EP - 63 JF - American journal of ophthalmology JO - Am. J. Ophthalmol. VL - 135 IS - 1 N2 - PURPOSE: To compare the intraocular pressure (IOP)-lowering efficacy and safety of topical bimatoprost 0.03% with latanoprost 0.005%. DESIGN: Multicenter, randomized, investigator-masked clinical trial. METHODS: After washout of glaucoma medications, ocular hypertension or glaucoma patients were randomly assigned to once-daily bimatoprost 0.03% (n = 133) or latanoprost 0.005% (n = 136) for 6 months. The primary outcome measure was mean change from baseline IOP (8 AM, 12 PM, 4 PM). Secondary measures included mean IOP, ophthalmologic examination, adverse events, and the percentage of patients reaching specific target IOPs. RESULTS: Mean change from baseline IOP was significantly greater for bimatoprost patients than for latanoprost patients at all measurements on each study visit; 1.5 mm Hg greater at 8 AM (P <.001), 2.2 mm Hg greater at 12 PM (P <.001), and 1.2 mm Hg greater at 4 PM (P =.004) at month 6. At the end of the study, the percentage of patients achieving a > or = 20% IOP decrease was 69% to 82% with bimatoprost and 50% to 62% with latanoprost (P < or = .003). In addition, the distribution of patients achieving target pressures in each range (< or = 13 to < or = 15 mm Hg, >15 to < or = 18 mm Hg, and > 18 mm Hg) showed that bimatoprost produced lower target pressures compared with latanoprost at all times measured (P < or = .026). Few patients were discontinued for adverse events (6 on bimatoprost; 5 on latanoprost). On ophthalmologic examination, conjunctival hyperemia (P <.001) and eyelash growth (P =.064) were more common in bimatoprost patients. CONCLUSIONS: Bimatoprost is more effective than latanoprost in lowering IOP. Both drugs were well tolerated, with few discontinuations for adverse events. SN - 0002-9394 UR - https://www.unboundmedicine.com/medline/citation/12504698/A_six_month_randomized_clinical_trial_comparing_the_intraocular_pressure_lowering_efficacy_of_bimatoprost_and_latanoprost_in_patients_with_ocular_hypertension_or_glaucoma_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002939402018275 DB - PRIME DP - Unbound Medicine ER -